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The African Origin of the Common Mutation in
African American Patients with Glycogen-Storage
Disease Type II
To the Editor:
Conventional historiographical research provides abun-
dant evidence of the African roots of African American
populations, but, because of the absence of complete
documentary records—for example, the point of em-
barkation of a particular slave vessel does not necessarily
indicate who was actually on that vessel, and slave car-
goes tended to be composed of mixed populations—it
remains a frustrating task to identify exactly who was
transported to the Americas (Curtin 1969; Parish 1989;
Thornton 1992). The presence of a genetic marker in
an African American population, however, might furnish
a verifiable link, for the individuals who carry the trait,
to a specific tribe or even to a point of origin.
In the autosomal recessive disorder glycogen-storage
disease type II (GSD II [MIM 232300]), a deficiency of
acid maltase (GAA; acid a-glucosidase) leads to the path-
ological accumulation of glycogen in lysosomes. In its
most severe form, progressive cardiomyopathy causes
cardiorespiratory failure and death within the 1st year
of life (Pompe syndrome). Among the mutations iden-
tified (see Lin and Shieh 1995; Raben et al. 1995; Tsun-
oda et al. 1996; Adams et al. 1997; reviewed by Reuser
et al. 1995; Hirschhorn and Huie 1997), three that lead
to the total loss of enzyme activity occur frequently in
particular ethnic groups: deletion of exon 18 in Cau-
casians (Boerkoel et al. 1992; Huie et al. 1994a; Van
der Kraan et al. 1994; Kroos et al. 1995), deletion of
T525 in northern Europeans (Hermans et al. 1994;
Kroos et al. 1995), and D645E in Chinese patients from
Taiwan (Shieh et al. 1994; Lin and Shieh 1996). The
chance to study several affected infants of African par-
ents has permitted us to identify a common African mu-
tation, to confirm our previous suggestion that the mu-
tation is also common in African Americans (Adams et
al. 1997), and, thereby, to explore the molecular roots
of GSD II in African Americans.
We initially studied a 3-mo-old infant (patient 1), from
the Ivory Coast, of healthy, nonconsanguineous parents;
the mother is Mandingo, and the father is Gue´re´ (table
1). The patient is a compound heterozygote harboring
a previously described C2560T transition in exon 18
(Hermans et al. 1993a; Adams et al. 1997) and a novel
T2846A transversion in exon 20. An unusual feature of
the novel exon 20 mutation (V949D) is its localization
at the carboxy terminus of the 952 amino acid precursor,
the tail that is removed during processing into mature
forms (Wisselaar et al. 1993). Expression studies showed
that the mutation results in complete inactivation of the
enzyme: catalytic activity of the mutant protein in trans-
fected COS cells did not exceed the background lev-
els—778, 30, and 26 nmol 4-4-methylumbelliferone/h/
mg cell protein for the wild-type, mutant, and mock-
transfected cells, respectively. The mature protein was
not detected by western analysis, thereby adequately ex-
plaining the absence of enzyme activity in this allele (data
not shown). Apparently, the mutation results in a deg-
radation of the precursor molecules prior to processing
and maturation.
The paternally inherited nonsense mutation in exon
18 (R854X), which resides on a silent allele, had been
previously described in a compound-heterozygous adult
African American patient (cell line GM 01935) (Her-
mans et al. 1993a) and in a half–African American (Af-
rican American father and Caucasian mother) child (pa-
tient 6) with the juvenile form of the disease (table 1).
The data thus strongly pointed to an African origin of
the R854X mutation in the African Americans and
prompted us to look for more patients of a similar back-
ground. Two other infants born of western African par-
ents were available for study. The R854X mutation was
present on one allele of a 2-mo-old infant (patient 2) of
healthy, nonconsanguineous parents who were of Hausa
origin. One parent was from the province of Katsina,
and the other was from the northeastern Borno province
(parental DNAs were not available); the patient’s male
sibling had died at age 5 mo, of unknown causes. Both
alleles of a 4-mo-old Ghanaian infant (patient 3) of
healthy, nonconsanguineous parents, who were from the
Twi subgroup of the Ashanti tribe and were living in
Accra, bore R854X. We also sought the mutation in
infants of different backgrounds who were from south-
ern Africa and who had been reported by van der Ploeg
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Table 1
Presence of R854X or Other Mutations on African or African
American Chromosomes
GROUP AND PATIENT
MUTATION STATUS OF
Chromosome 1 Chromosome 2
African:
Patient 1 (Ivory Coast) R854X V949D
Patient 2 (Nigeria) R854X Negativea
Patient 3 (Ghana) R854X R854X
Patient 4 (Ovambo-Namibia) R854X R854X
Patient 5 (Zulu-South Africa) Negative Negative
African American:b
Patient 6 (mixed) R854X IVS6 22 trg
Patient 7 R854X Negative
Patient 8 R854X Negative
Patient 9 (C2123) R854X R854X
Patient 10 (C1992) Negative Negative
Patient 11 (C9752) Negative Negative
GM 00248 R854X R854X
GM 00338 R854X R854X
GM 01935 R854X D654E
GM 03329 Negative M519V
GM 04912 Negative Negative
GM 12932 Negative Negative
NOTE.—This study was carried out under protocols approved by
the institutional review boards of the National Institute of Arthritis
and Musculoskeletal and Skin Diseases and of the institutions where
the samples were obtained. Details of the primers, PCR conditions,
and identification of mutations are available on request.
a R854X not present.
b Patient 6 has been reported in detail elsewhere (Adams et al. 1997).
Patient 7 was the 6-wk-old daughter of healthy, nonconsanguineous
African American parents; patient 8 was a 6-mo-old African American
male referred to New York University Medical Center by Dr. H. Mus-
sel; patients 9–11 (C2123, C1992, and C9752) were referred to the
New York State Institute for Basic Research and New York University
Medical Center. The cell lines designated “GM” were obtained from
the National Institutes of Health Mutant Repository, Coriell Cell Re-
positories (Camden, NJ) and were derived from African American
patients with infantile-onset GSD II (GM 00248, GM 12932, GM
03329, GM 00338, and GM 04912) (Martiniuk et al. 1986; Zhong
et al. 1991) or adult-onset GSD II (GM 01935). Additional clinical
information is present in the Coriell catalogue. Mutations and addi-
tional molecular information have been reported for GM 03329 (Huie
et al. 1994b) and GM 01935 (Martiniuk et al. 1991; Hermans et al.
1993a). The diagnosis of severe deficiency of GAA was demonstrated
in each of these patients by enzymatic assay of fibroblasts and/or
muscle.
et al. (1989). Both alleles of an Ovambo infant (patient
4) from Namibia carried R854X, and a Zulu infant (pa-
tient 5) was negative. (R854X was also absent in the
two infants from southern Africa who were of uncertain
ethnic background.) R854X was present, therefore, in
four of five African infants of known ethnic background,
on 6 of 10 chromosomes.
Among the 12 African American patients studied (pa-
tients 6–11 and six GM cell lines), 3 are homozygous,
and 4 are heterozygous, for R854X (table 1). Therefore,
10 of 23 African American chromosomes (the mother
of patient 6 is Caucasian) carry the R854X mutation,
resulting in an allele frequency of .43 among African
Americans with GSD II.
The other mutation described in an African American
(Hermans et al. 1993a) and also identified in Chinese
patients—that is, D645E—was not found in any of our
cases. In African American patients (Hermans et al.
1993b) but not Chinese patients (C-Y Lin, personal com-
munication), the mutation is associated with two poly-
morphic sites in exons 17 and 19 (I816 and I927) found
in several healthy unrelated African Americans, sug-
gesting that the Chinese and African American D645E
mutations occurred independently. By contrast, all eight
polymorphic sites (596G, 668A, 921T, 1203A, 1374T,
2154C, 2338A, and 2553A) residing on the R854X mu-
tated African American allele in our juvenile case (Ad-
ams et al. 1997) are identical to those found in the in-
fants from the Ivory Coast, Ghana, and Namibia, a
finding that suggests a common haplotype and a com-
mon origin of the R854X mutation.
The R854X mutation was not found in 7 infantile-
and 34 adult-onset Caucasian patients with GSD II. This
represents 48 chromosomes at risk for a “null” muta-
tion: 2 from each infant and only 1 from each adult,
since adult patients have some enzyme activity. These
results clearly document that R854X is not frequent in
all populations. However, the mutation was found in
homozygosity in an infantile patient from consanguin-
eous Pakistani parents and was found in heterozygosity
in a Mexican American patient and in a French patient.
The R854X mutation is a CrT transition at a CG dinu-
cleotide and therefore is at a site susceptible to recurrent
mutations. Further investigation of haplotypes could re-
veal whether these are independently recurring events.
Of the 12 million African captives, !600,000 ever
reached North American shores. The slave trade to
North America experienced two particularly strong pe-
riods: one just before the American Revolution of 1776,
and the second at the turn of the 19th century, just before
the passage, in 1808, of a law prohibiting the impor-
tation of African slaves (Rawley 1985). The first Africans
to be enslaved in the 16th century were peoples from
the western Atlantic region. Traders then worked their
way incrementally along the coast, focusing next on
Guinea Coast peoples, and, at the height of the late-18th
century trade, peoples of the Guinea Coast, often of
Ashanti origin, were most common in slave cargoes. The
trade eventually reached Angola, around 1800 (Curtin
1969).
The four African ethnic groups currently known to
carry R854X (fig. 1) have a history of long-standing
interaction. The Hausa, although they claim northern
Nigeria as their homeland, are widely dispersed through-
out western Africa. Their commercial activities, initiated
as early as 1100, brought them into direct and prolonged
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Figure 1 Geographic location of western African populations
described in the text.
contact with the western Atlantic region, where they
encountered the Gue´re´ of the Ivory Coast. The Gue´re´,
in turn, were a subgroup of the Kru who, because of
their boating skills, were used as deckhands on European
trading vessels sailing in Africa’s coastal waters. The
Hausa also had strong contacts with the Ashanti nation,
in what is today the nation of Ghana, both through trade
connections and through residential enclaves. The
Ovambo of Namibia, although they were beyond the
reach of the Hausa trade network, are a Bantu-speaking
group descended from a population originally located
on the Bauchi plateau of northern Nigeria, adjacent to
the Hausa homelands. Segments of this Nigerian group,
who would eventually become the Ovambo, undertook
a gradual southward migration that brought them to
their current location in Angola and northern Namibia,
sometime during the period of 800–900 (Turnbull 1977;
Curtin and Bohannon 1988). Thus, although it is prob-
able that the closest African ancestors of the African
American patients were culturally Ashanti and were
brought to North America from the Guinea Coast, their
genetic makeup strongly suggests that they have Hausa
roots. It is reasonable to speculate that the mutation
occurred some time before the southward migration of
the Ovambo away from the territory of the Hausas,
possibly in their common ancestral population from
north-central Africa.
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